Table 4 Clinicopathological characteristics of patients who received PARPi retreatment

N

14

Median age (Range)

51.5 (38–76)

Age at diagnosis (y)

< 50

6

42.9

≥50

14

100.0

Tumor size (cm)

<5

3

21.4

≥ 5

11

78.6

Primary tumor location

Ovary

13

92.9

Fallopian tube

1

7.1

Histology

Serous

14

100.0

Clear cell cancer

0

0.0

FIGO Stage

III

10

71.4

IV

4

28.6

Neoadjuvant chemotherapy

Yes

7

50.0

No

7

50.0

Postoperative residual disease status

Optimal (R0/R1)

12

85.7

Suboptimal (≥ R1)

2

14.3

PARPi 1 received

Fluzoparib

1

7.1

Olaprib

5

35.7

Niraparib

8

57.1

2 L chemotherapy regimens

Platinum-based chemotherapy

13

92.9

Non-platinum-based chemotherapy

1

7.1

PARPi 2 received

Fluzoparib

1

7.1

Olaprib

5

35.7

Niraparib

8

57.1

HRR status

BRCA1 mt

1

7.1

BRCA2 mt

1

7.1

Non-BRCA HRR mt

2

14.3

WT

10

71.4

First recurrence

Platinum-sensitive recurrence

14

100.0

Platinum-resistant recurrence

0

0.0

Second recurrence

Platinum-sensitive recurrence

6

54.5

Platinum-resistant recurrence

5

45.5

NA

3